We're buying the dip in what we think is one of the most promising early stage AI stocks͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| |  | | April 2, 2024 | | Alert Action to Take: Buy RXRX up to $10 Dear Leah, Today, the markets are bleeding out – but as we’ve said, we’re staying in buy-the-dip mode.
We’re confident that we’re just experiencing some short-term turbulence before a powerful stock market rally that lasts into the summer, powered by strong earnings, soft inflation, and a few rate cuts from the Fed.
From our perspective, it’s still “buying season,” so we aren’t running away from this stock market selloff. We’re embracing it.
Today, we’re buying the dip in what we think is one of the most promising early stage AI stocks, which is sporting some major upside potential over the next few years.
We’re talking about Recursion Pharmaceuticals (RXRX). Read the Full Alert |  | | Luke Lango
Editor, Innovation Investor Click here to access Innovation Investor’s Special Report archive.
Get more from your subscription by reading our owner’s manual and using our brand-new Portfolio Tracker.
To cancel your subscription, call the number in the footer below. | | | | |
Tidak ada komentar:
Posting Komentar